Luteolin Inhibits Human Prostate Tumor Growth by Suppressing Vascular Endothelial Growth Factor Receptor 2-Mediated Angiogenesis

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Pratheeshkumar, Poyil ^a   Son, Young Ok ^a   Budhraja, Amit ^a   Wang, Xin ^a   Ding, Songze ^a   Wang, Lei ^a   Hitron, Andrew ^a   Lee, Jeong Chae ^a   Kim, Donghern ^a   Divya, Sasidharan Padmaja ^b   Chen, Gang ^a   Zhang, Zhuo ^a   Luo, Jia ^a   Shi, Xianglin ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Department of Physics   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LUTEOLIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; S6 KINASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROVASCULATURE; NONHUMAN; PROSTATE TUMOR; PROTEIN PHOSPHORYLATION; RAT; TUMOR VASCULARIZATION;

ANIMALS; AORTA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; CYTOKINES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LUTEOLIN; MALE; MATRIX METALLOPROTEINASES; MICE; MICROVESSELS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

RATTUS;

EID: 84871729357     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052279     Document Type: Article

References (77)

1. McMahon G, (2000) VEGF receptor signaling in tumor angiogenesis. The Oncologist 5: 3-10.
2. Pratheeshkumar P, Kuttan G (2011) Vernolide-A inhibits tumour specific angiogenesis by regulating proinflammatory cytokines, VEGF, MMPs and TIMP. European journal of pharmacology.
3. Ferrara N, Gerber HP, LeCouter J, (2003) The biology of VEGF and its receptors. Nature medicine 9: 669-676.
4. Zachary I, Gliki G, (2001) Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovascular research 49: 568-581.
5. Cho CH, Lee CS, Chang M, Jang IH, Kim SJ, et al. (2004) Localization of VEGFR-2 and PLD2 in endothelial caveolae is involved in VEGF-induced phosphorylation of MEK and ERK. American Journal of Physiology-Heart and Circulatory Physiology 286: H1881-H1888.
6. Kim BW, Choi M, Kim YS, Park H, Lee HR, et al. (2008) Vascular endothelial growth factor (VEGF) signaling regulates hippocampal neurons by elevation of intracellular calcium and activation of calcium/calmodulin protein kinase II and mammalian target of rapamycin. Cellular signalling 20: 714-725.
7. Viñals F, Chambard JC, Pouysségur J, (1999) p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. Journal of Biological Chemistry 274: 26776-26782.
8. Bouraoui Y, Ricote M, García-Tuñón I, Rodriguez-Berriguete G, Touffehi M, et al. (2008) Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer. Cancer detection and prevention 32: 23-32.
9. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G, (2006) Inflammation and cancer: how hot is the link? Biochemical pharmacology 72: 1605-1621.
10. Isner JM, Asahara T, (1999) Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. Journal of Clinical Investigation 103: 1231-1236.
11. Pratheeshkumar P, Kuttan G (2011) Nomilin inhibits tumor-specific angiogenesis by downregulating VEGF, NO and proinflammatory cytokine profile and also by inhibiting the activation of MMP-2 and MMP-9. European journal of pharmacology.
12. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, et al. (1999) Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clinical cancer research 5: 1369-1379.
13. Hidalgo M, Eckhardt SG, (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. Journal of the National Cancer Institute 93: 178-193.
14. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Risberg B, et al. (2003) Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: A possible activation pathway? Cancer and Metastasis Reviews 22: 103-115.
15. Weng CJ, Yen GC (2012) Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. Cancer and Metastasis Reviews: 1-29.
16. Lim DY, Jeong Y, Tyner AL, Park JHY, (2007) Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. American Journal of Physiology-Gastrointestinal and Liver Physiology 292: G66-G75.
17. Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, et al. (2006) Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer research 66: 4826.
18. Lee WJ, Wu LF, Chen WK, Wang CJ, Tseng TH, (2006) Inhibitory effect of luteolin on hepatocyte growth factor/scatter factor-induced HepG2 cell invasion involving both MAPK/ERKs and PI3K-Akt pathways. Chemico-biological interactions 160: 123-133.
19. Attoub S, Hassan AH, Vanhoecke B, Iratni R, Takahashi T, et al. (2011) Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. European journal of pharmacology 651: 18-25.
20. Pratheeshkumar P, Kuttan G, (2011) Vernolide-A, a sesquiterpene lactone from Vernonia cinerea, induces apoptosis in B16F-10 melanoma cells by modulating p53 and caspase-3 gene expressions and regulating NF-κB-mediated bcl-2 activation. Drug and Chemical Toxicology 34: 261-270.
21. Pratheeshkumar P, Kuttan G, (2011) Andrographolide inhibits human umbilical vein endothelial cell invasion and migration by regulating MMP-2 and MMP-9 during angiogenesis. Journal of environmental pathology, toxicology and oncology: official organ of the International Society for Environmental Toxicology and Cancer 30: 33.
22. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, et al. (2008) Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Molecular cancer therapeutics 7: 1789.
23. Pang X, Yi Z, Zhang X, Sung B, Qu W, et al. (2009) Acetyl-11-Keto-β-Boswellic Acid Inhibits Prostate Tumor Growth by Suppressing Vascular Endothelial Growth Factor Receptor 2-Mediated Angiogenesis. Cancer research 69: 5893.
24. Liu LZ, Jiang Y, Carpenter RL, Jing Y, Peiper SC, et al. (2011) Role and Mechanism of Arsenic in Regulating Angiogenesis. PloS one 6: e20858.
25. Billings PC, Habres JM, Liao DC, Tuttle SW, (1991) Human fibroblasts contain a proteolytic activity which is inhibited by the Bowman-Birk protease inhibitor. Cancer research 51: 5539.
26. Gao N, Kramer L, Rahmani M, Dent P, Grant S, (2006) The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1, 3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Molecular pharmacology 70: 645-655.
27. Patan S (2004) Vasculogenesis and angiogenesis. Angiogenesis in Brain Tumors: 3-32.
28. Lin C, Wu M, Dong J, (2012) Quercetin-4′-O-β-D-glucopyranoside (QODG) Inhibits Angiogenesis by Suppressing VEGFR2-Mediated Signaling in Zebrafish and Endothelial Cells. PloS one 7: e31708.
29. Berger NA (2010) Poly (ADP-ribose) in the cellular response to DNA damage.
30. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, et al. (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis.
31. Cohen GM, (1997) Caspases: the executioners of apoptosis. Biochemical Journal 326: 1.
32. Rhun YL, Kirkland J, Shah GM, (1998) Cellular responses to DNA damage in the absence of poly (ADP-ribose) polymerase. Biochemical and biophysical research communications 245: 1-10.
33. Matsuo M, Yamada S, Koizumi K, Sakurai H, Saiki I, (2007) Tumour-derived fibroblast growth factor-2 exerts lymphangiogenic effects through Akt/mTOR/p70S6kinase pathway in rat lymphatic endothelial cells. European Journal of Cancer 43: 1748-1754.
34. Li W, Tan D, Zhang Z, Liang JJ, Brown RE, (2008) Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncology reports 20: 713-719.
35. Risau W, (1997) Mechanisms of angiogenesis. Nature 386: 671-674.
36. Bhat TA, Singh RP, (2008) Tumor angiogenesis-a potential target in cancer chemoprevention. Food and Chemical Toxicology 46: 1334-1345.
37. Tozer GM, Kanthou C, Baguley BC, (2005) Disrupting tumour blood vessels. Nature Reviews Cancer 5: 423-435.
38. Bellon G, Martiny L, Robinet A, (2004) Matrix metalloproteinases and matrikines in angiogenesis. Critical reviews in oncology/hematology 49: 203-220.
39. Neal CP, Berry DP, (2006) Basic principles of the molecular biology of cancer II: angiogenesis, invasion and metastasis. Surgery (Oxford) 24: 120-125.
40. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. NATURE-LONDON-: 249-257.
41. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ, (1998) Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95: 365-377.
42. Sounni NE, Janssen M, Foidart JM, Noël A, (2003) Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix biology 22: 55-61.
43. Klagsbrun M, Moses MA, (1999) Molecular angiogenesis. Chemistry & biology 6: R217-R224.
44. Genís L, Gálvez BG, Gonzalo P, Arroyo AG, (2006) MT1-MMP: Universal or particular player in angiogenesis? Cancer and Metastasis Reviews 25: 77-86.
45. Lu R, Wang X, Chen ZF, Sun DF, Tian XQ, et al. (2007) Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells. Journal of Biological Chemistry 282: 12249-12259.
46. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, et al. (1998) Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer research 58: 1048-1051.
47. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, et al. (1998) MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93: 411-422.
48. Lindstad RI, Sylte I, Mikalsen SO, Seglen PO, Berg E, et al. (2005) Pancreatic trypsin activates human promatrix metalloproteinase-2. Journal of molecular biology 350: 682-698.
49. Hong J, Ahn K, Bae E, Jeon S, Choi H, (2006) The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate cancer and prostatic diseases 9: 147-152.
50. Lázár-Molnár E, Hegyesi H, Tóth S, Falus A, (2000) Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12: 547-554.
51. Anderson GM, Nakada MT, DeWitte M, (2004) Tumor necrosis factor-α in the pathogenesis and treatment of cancer. Current opinion in pharmacology 4: 314-320.
52. Sheen-Chen SM, Chen WJ, Eng HL, Chou FF, (1997) Serum concentration of tumor necrosis factor in patients with breast cancer. Breast cancer research and treatment 43: 211-215.
53. Weinreich DM, Elaraj DM, Puhlmann M, Hewitt SM, Carroll NM, et al. (2003) Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice. Cancer research 63: 5957.
54. Saijo Y, Tanaka M, Miki M, Usui K, Suzuki T, et al. (2002) Proinflammatory cytokine IL-1β promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. The Journal of Immunology 169: 469-475.
55. Akira S, Hirano T, Taga T, Kishimoto T, (1990) Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). The FASEB Journal 4: 2860-2867.
56. Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, et al. (2003) Elevated Production of Interleukin-6 Is Associated With a Lower Incidence of Disease-Related Ischemic Events in Patients With Giant-Cell Arteritis. Circulation 107: 2428-2434.
57. Maruo N, Morita I, Shirao M, Murota S, (1992) IL-6 increases endothelial permeability in vitro. Endocrinology 131: 710-714.
58. Lai Y, Liu X, Zeng Y, Zhang Y, Shen Y, et al. (2012) Interleukin-8 induces the endothelial cell migration through the Rac1/RhoA-p38MAPK pathway. Cell 51: 38MAPK.
59. Petzelbauer P, Watson CA, Pfau SE, Pober JS, (1995) IL-8 and angiogenesis: evidence that human endothelial cells lack receptors and do not respond to IL-8 in vitro. Cytokine 7: 267-272.
60. Relf M, LeJeune S, Scott PAE, Fox S, Smith K, et al. (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer research 57: 963.
61. Coultas L, Chawengsaksophak K, Rossant J, (2005) Endothelial cells and VEGF in vascular development. Nature 438: 937-945.
62. Ferrara N, (2002) VEGF and the quest for tumour angiogenesis factors. Nature Reviews Cancer 2: 795-803.
63. Shibuya M, Claesson-Welsh L, (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Experimental cell research 312: 549-560.
64. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L, (2006) VEGF receptor signalling? In control of vascular function. Nature Reviews Molecular Cell Biology 7: 359-371.
65. Baek JH, Jang JE, Kang CM, Chung HY, Kim ND, et al. (2000) Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 19: 4621.
66. Donà M, Dell'Aica I, Pezzato E, Sartor L, Calabrese F, et al. (2004) Hyperforin inhibits cancer invasion and metastasis. Cancer research 64: 6225.
67. Pang X, Yi Z, Zhang J, Lu B, Sung B, et al. (2010) Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer research 70: 1951.
68. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, et al. (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer research 62: 4645.
69. Yap TA, Garrett MD, Walton MI, Raynaud F, De Bono JS, et al. (2008) Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Current opinion in pharmacology 8: 393-412.
70. Manning BD, Cantley LC, (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
71. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, et al. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605.
72. Semenza GL, (2003) Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 3: 721-732.
73. Gordan JD, Simon MC, (2007) Hypoxia-inducible factors: central regulators of the tumor phenotype. Current opinion in genetics & development 17: 71-77.
74. Fasolo A, Sessa C (2008) mTOR inhibitors in the treatment of cancer.
75. Chen J, Fang Y, (2002) A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochemical pharmacology 64: 1071-1077.
76. Liu L, Cao Y, Chen C, Zhang X, McNabola A, et al. (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer research 66: 11851.
77. Olszewska-Pazdrak B, Hein TW, Olszewska P, Carney DH, (2009) Chronic hypoxia attenuates VEGF signaling and angiogenic responses by downregulation of KDR in human endothelial cells. American Journal of Physiology-Cell Physiology 296: C1162-C1170.